Comparing SeaStar Medical (NASDAQ:ICU) and BG Medicine (OTCMKTS:BGMD)

BG Medicine (OTCMKTS:BGMD) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Risk & Volatility

BG Medicine has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its share price is 205% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for BG Medicine and SeaStar Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BG Medicine	0	0	0	0	0.00
SeaStar Medical	1	0	1	0	2.00

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 126.63%. Given SeaStar Medical’s stronger consensus rating and higher possible upside, analysts clearly believe SeaStar Medical is more favorable than BG Medicine.

Earnings and Valuation

This table compares BG Medicine and SeaStar Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BG Medicine	N/A	N/A	N/A	N/A	N/A
SeaStar Medical	$1.23 million	11.48	-$12.15 million	($4.80)	-0.74

BG Medicine has higher earnings, but lower revenue than SeaStar Medical.

Institutional & Insider Ownership

1.7% of SeaStar Medical shares are owned by institutional investors. 6.5% of BG Medicine shares are owned by insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares BG Medicine and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BG Medicine	N/A	N/A	N/A
SeaStar Medical	-828.62%	-146.29%	-96.48%

About BG Medicine

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.